Sexually Transmitted Disease (STD) Testing Market Size, Share, Trends, Growth Outlook

Sexually Transmitted Disease (STD) Testing Market is estimated to increase at a growth rate of 7.3% CAGR over the forecast period from 2024 to 2030.

The global Sexually Transmitted Disease (STD) Testing Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Disease (Chlamydia, Gonorrhea, Herpes simplex virus, Syphilis, Human papillomavirus (HPV), Others), By Testing (Laboratory testing, Point of care (POC) testing).

An Introduction to Sexually Transmitted Disease (STD) Testing Market in 2024

The Sexually Transmitted Disease (STD) Testing Market encompasses diagnostic tests, molecular assays, point-of-care devices, and screening kits used for the detection of sexually transmitted infections (STIs) such as HIV/AIDS, chlamydia, gonorrhea, syphilis, hepatitis, herpes, and human papillomavirus (HPV). STD testing modalities include nucleic acid amplification tests (NAATs), serological assays, rapid diagnostic tests (RDTs), and self-testing kits for confidential and convenient STI screenings in healthcare settings, clinics, laboratories, and home use. Market dynamics focus on public health initiatives, STI prevention campaigns, telemedicine testing services, and technological advancements in rapid and accurate STD diagnostics for early intervention and disease control.

Sexually Transmitted Disease (STD) Testing Market Competitive Landscape

The global Sexually Transmitted Disease (STD) Testing Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Sexually Transmitted Disease (STD) Testing Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Sexually Transmitted Disease (STD) Testing Industry include- AccuBioTech Co. Ltd, AdvaCare Pharma, BIOGENIX Inc Pvt. Ltd, CTK Biotech Inc, Everlywell Inc, F. Hoffmann La Roche Ltd, Gilead Sciences Inc, GlaxoSmithKline Plc, Goffin Molecular Technologies, Hangzhou Biotest Biotech Co. Ltd, Hologic Inc, Inovio Pharmaceuticals Inc, Johnson and Johnson, LT Labs, Merck and Co. Inc.

Sexually Transmitted Disease Testing Market Trend: Rise in At-Home Testing Kits

In the Sexually Transmitted Disease (STD) Testing market, a significant trend is the increasing availability and utilization of at-home testing kits. With advancements in technology and consumer preferences shifting towards convenience and privacy, there's a growing demand for self-administered STD testing kits that allow individuals to discreetly collect samples at home and send them to laboratories for analysis. This trend reflects a broader shift towards telehealth and remote healthcare services, enabling individuals to access essential diagnostic testing without visiting traditional healthcare facilities.

Sexually Transmitted Disease Testing Market Driver: Growing Awareness and Screening Efforts

The primary driver for the STD Testing market is the growing awareness of sexually transmitted diseases and efforts to promote regular screening and early detection. Public health campaigns, educational initiatives, and advocacy efforts aim to destigmatize STD testing, encourage open communication about sexual health, and increase testing rates among at-risk populations. As individuals become more informed about the importance of regular screening for STDs, there's an increasing demand for accessible and convenient testing options that facilitate proactive healthcare-seeking behaviors and reduce the transmission of infectious diseases.

Sexually Transmitted Disease Testing Market Opportunity: Integration of Point-of-Care Testing Technologies

An opportunity exists in the integration of point-of-care testing (POCT) technologies into STD testing platforms to enhance accessibility, speed, and accuracy of diagnostic testing. POCT devices enable rapid detection of STDs at the point of care, allowing healthcare providers to deliver timely interventions, initiate treatment, and provide counseling services during a single patient visit. By investing in the development of POCT devices for STD testing and expanding their use in clinical settings, diagnostic companies can address the need for faster turnaround times, improve patient satisfaction, and facilitate timely management of sexually transmitted infections. Additionally, integrating POCT technologies with telemedicine platforms and mobile health apps could further enhance access to STD testing services and support remote healthcare delivery models.

Sexually Transmitted Disease Testing Market Share Analysis: Point of Care (POC) Testing for Chlamydia is the fastest growing market segment over the forecast period to 2030

Point of care (POC) testing for Chlamydia emerges as the fastest-growing segment in the sexually transmitted disease (STD) testing market. Chlamydia is one of the most common bacterial STDs globally, and its prevalence has been steadily increasing in recent years. POC testing offers several advantages over traditional laboratory testing, including rapid results, convenience, and accessibility. With POC testing, individuals can receive their test results within minutes, enabling timely diagnosis and treatment initiation. This is particularly crucial for Chlamydia, as untreated infections can lead to severe complications such as pelvic inflammatory disease and infertility. Additionally, POC testing allows for testing in non-clinical settings such as community health centers, outreach programs, and even home testing kits, thereby reaching underserved populations and improving access to testing services. As a result of these factors, POC testing for Chlamydia is experiencing rapid growth and is expected to continue expanding as healthcare providers and policymakers prioritize early detection and intervention strategies to curb the spread of this prevalent STD.

Sexually Transmitted Disease (STD) Testing Market Segmentation

By Disease
Chlamydia
Gonorrhea
Herpes simplex virus
Syphilis
Human papillomavirus (HPV)
Others
By Testing
Laboratory testing
Point of care (POC) testing
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Sexually Transmitted Disease (STD) Testing Companies

AccuBioTech Co. Ltd
AdvaCare Pharma
BIOGENIX Inc Pvt. Ltd
CTK Biotech Inc
Everlywell Inc
F. Hoffmann La Roche Ltd
Gilead Sciences Inc
GlaxoSmithKline Plc
Goffin Molecular Technologies
Hangzhou Biotest Biotech Co. Ltd
Hologic Inc
Inovio Pharmaceuticals Inc
Johnson and Johnson
LT Labs
Merck and Co. Inc
* List not Exhaustive

Reasons to Buy the Sexually Transmitted Disease (STD) Testing Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Sexually Transmitted Disease (STD) Testing Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Sexually Transmitted Disease (STD) Testing Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Sexually Transmitted Disease (STD) Testing Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Sexually Transmitted Disease (STD) Testing Market Size Outlook, $ Million, 2021 to 2030
3.2 Sexually Transmitted Disease (STD) Testing Market Outlook by Type, $ Million, 2021 to 2030
3.3 Sexually Transmitted Disease (STD) Testing Market Outlook by Product, $ Million, 2021 to 2030
3.4 Sexually Transmitted Disease (STD) Testing Market Outlook by Application, $ Million, 2021 to 2030
3.5 Sexually Transmitted Disease (STD) Testing Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Sexually Transmitted Disease (STD) Testing Industry
4.2 Key Market Trends in Sexually Transmitted Disease (STD) Testing Industry
4.3 Potential Opportunities in Sexually Transmitted Disease (STD) Testing Industry
4.4 Key Challenges in Sexually Transmitted Disease (STD) Testing Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Sexually Transmitted Disease (STD) Testing Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Sexually Transmitted Disease (STD) Testing Market Outlook by Segments
7.1 Sexually Transmitted Disease (STD) Testing Market Outlook by Segments, $ Million, 2021- 2030
By Disease
Chlamydia
Gonorrhea
Herpes simplex virus
Syphilis
Human papillomavirus (HPV)
Others
By Testing
Laboratory testing
Point of care (POC) testing
8 North America Sexually Transmitted Disease (STD) Testing Market Analysis and Outlook To 2030
8.1 Introduction to North America Sexually Transmitted Disease (STD) Testing Markets in 2024
8.2 North America Sexually Transmitted Disease (STD) Testing Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Sexually Transmitted Disease (STD) Testing Market size Outlook by Segments, 2021-2030
By Disease
Chlamydia
Gonorrhea
Herpes simplex virus
Syphilis
Human papillomavirus (HPV)
Others
By Testing
Laboratory testing
Point of care (POC) testing
9 Europe Sexually Transmitted Disease (STD) Testing Market Analysis and Outlook To 2030
9.1 Introduction to Europe Sexually Transmitted Disease (STD) Testing Markets in 2024
9.2 Europe Sexually Transmitted Disease (STD) Testing Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Sexually Transmitted Disease (STD) Testing Market Size Outlook by Segments, 2021-2030
By Disease
Chlamydia
Gonorrhea
Herpes simplex virus
Syphilis
Human papillomavirus (HPV)
Others
By Testing
Laboratory testing
Point of care (POC) testing
10 Asia Pacific Sexually Transmitted Disease (STD) Testing Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Sexually Transmitted Disease (STD) Testing Markets in 2024
10.2 Asia Pacific Sexually Transmitted Disease (STD) Testing Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Sexually Transmitted Disease (STD) Testing Market size Outlook by Segments, 2021-2030
By Disease
Chlamydia
Gonorrhea
Herpes simplex virus
Syphilis
Human papillomavirus (HPV)
Others
By Testing
Laboratory testing
Point of care (POC) testing
11 South America Sexually Transmitted Disease (STD) Testing Market Analysis and Outlook To 2030
11.1 Introduction to South America Sexually Transmitted Disease (STD) Testing Markets in 2024
11.2 South America Sexually Transmitted Disease (STD) Testing Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Sexually Transmitted Disease (STD) Testing Market size Outlook by Segments, 2021-2030
By Disease
Chlamydia
Gonorrhea
Herpes simplex virus
Syphilis
Human papillomavirus (HPV)
Others
By Testing
Laboratory testing
Point of care (POC) testing
12 Middle East and Africa Sexually Transmitted Disease (STD) Testing Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Sexually Transmitted Disease (STD) Testing Markets in 2024
12.2 Middle East and Africa Sexually Transmitted Disease (STD) Testing Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Sexually Transmitted Disease (STD) Testing Market size Outlook by Segments, 2021-2030
By Disease
Chlamydia
Gonorrhea
Herpes simplex virus
Syphilis
Human papillomavirus (HPV)
Others
By Testing
Laboratory testing
Point of care (POC) testing
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AccuBioTech Co. Ltd
AdvaCare Pharma
BIOGENIX Inc Pvt. Ltd
CTK Biotech Inc
Everlywell Inc
F. Hoffmann La Roche Ltd
Gilead Sciences Inc
GlaxoSmithKline Plc
Goffin Molecular Technologies
Hangzhou Biotest Biotech Co. Ltd
Hologic Inc
Inovio Pharmaceuticals Inc
Johnson and Johnson
LT Labs
Merck and Co. Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Disease
Chlamydia
Gonorrhea
Herpes simplex virus
Syphilis
Human papillomavirus (HPV)
Others
By Testing
Laboratory testing
Point of care (POC) testing